$Ironwood Pharmaceuticals (IRWD.US)$🎯 2023.8.24 Current pri...

New data: 2023Q2

Revenue increased by 10.4% in 2023Q2, and operating profit was affected by the acquisition of In-Process Research and Development (In-Process Research and Development) and a loss of 1.07 billion dollars. However, this ongoing R&D included investment cash flow in the cash flow statement. Even so, net cash flow operating volume fell by 43% in the 2nd quarter.

The balance sheet shows that cash fell by 560 million dollars, long-term and short-term loans increased by a total of 400 million yuan, and net assets became negative at 350 million dollars.

Currently, it seems that this acquisition uses excessive debt leverage. The risk is extremely high, and the position has been temporarily closed.